Cost benefit analysis of the use of tranexamic acid in primary lower limb arthroplasty: A retrospective cohort study

Table 1 Patient demographics

	Control group(n = 100)	TXA group(n = 100)	P value
Male/female	49/51	44/56	0.47
Age in years	62.57 ± 12.14	62.9 ± 12.6	0.86
THR/TKR	60/40	52/48	0.25
Pre-operative Hgb	13.61 ± 1.42	13.77 ± 1.41	0.43
Pre-operative Hct	0.41 ± 0.04	0.41 ± 0.04	0.32
Pre-operative platelets	253.01 ± 55.87	256.85 ± 69.75	0.67

THR: Total hip replacement; TKR: Total knee replacement; Hgb: Haemoglobin; Hct: Haematocrit; TXA: Tranexamic acid.

Table 2 Differences between the groups following surgery

	Control group(n = 100)	TXA group(n = 100)	P value
Post-operative Hgb	10.82 ± 1.55	11.33 ± 1.27	0.01
Post-operative Hct	0.32 ± 0.05	0.34 ± 0.04	0.01
Post-operative platelets	204.32 ± 44.68	212.22 ± 52.49	0.25
Mean length of stay in hospital in days	6.53 ± 5.92	5.47 ± 4.26	0.15

Hgb: Haemoglobin; Hct: Haematocrit; TXA: Tranexamic acid.

Table 3 Cost analysis

	Control group(n = 100)	TXA group(n = 100)	Difference
No. of patients transfused	22	2	20
No. of units transfused	55	3	52
Total cost of transfusion	€11055	€603	€10452
BDU	653	547	106
Total cost of BDU	€705893	€591307	€114586

BDU: Bed days used; TXA: Tranexamic acid.